Standout Papers

Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients... 1996 2026 2006 2016 1.9k
  1. Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy (2004)
    Nasser H. Hanna, Frances A. Shepherd et al. Journal of Clinical Oncology
  2. Tumor Marker Utility Grading System: a Framework to Evaluate Clinical Utility of Tumor Markers (1996)
    D. F. Hayes, Robert C. Bast et al. JNCI Journal of the National Cancer Institute
  3. Hospital and Physician Volume or Specialization and Outcomes in Cancer Treatment: Importance in Quality of Cancer Care (2000)
    Bruce E. Hillner, Thomas J. Smith et al. Journal of Clinical Oncology

Immediate Impact

6 by Nobel laureates 4 from Science/Nature 82 standout
Sub-graph 1 of 16

Citing Papers

Selpercatinib in Patients With RET Fusion–Positive Non–Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial
2022 Standout
The mucin-selective protease StcE enables molecular and functional analysis of human cancer-associated mucins
2019 StandoutNobel
1 intermediate paper

Works of Christopher E. Desch being referenced

Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
2004 Standout

Author Peers

Author Last Decade Papers Cites
Christopher E. Desch 3815 739 2879 892 64 6.0k
Philip C. Prorok 3037 299 3094 788 131 6.4k
Jean-Yves Douillard 3023 367 3029 834 70 5.5k
Boštjan Šeruga 4311 461 1795 1594 123 7.2k
Laura F. Hutchins 3952 497 1673 1448 120 7.1k
Yu‐Ning Wong 2035 658 1613 1385 129 4.9k
Rosemary Yancik 3705 613 1344 867 39 6.6k
M.L.G. Janssen‐Heijnen 3972 453 1989 837 127 6.7k
Christina Lacchetti 3695 314 1334 624 62 6.5k
Lazzaro Repetto 2915 708 1376 446 100 6.1k
Veena Shankaran 3396 1550 1531 604 111 5.7k

All Works

Loading papers...

Rankless by CCL
2026